Tanzeum (albiglutide) / GSK - LARVOL DELTA

Risk of Cutaneous Adverse Drug Reactions with GLP-1 Receptor Agonists: Insights from FAERS and Systematic Review (ISPOR 2025) - "Liraglutide was linked to injection site urticaria (n=197; PRR=6.0; chisq=797.6), dulaglutide to injection site hypersensitivity (n=61; PRR=8.4; chisq=373.4), and albiglutide to injection site rash (n=43; PRR=12.8; chisq=454.2). Findings from the FAERS database and systematic review demonstrate a significant association between GLP-1 RAs and CADRs, ranging from localized to rare systemic reactions. Carefully monitoring CADRs in patients using GLP-1 RAs is essential to optimizing treatment safety, improving outcomes, and ensuring the overall well-being of patients undergoing this therapy."

Adverse drug reaction • Review • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • Urticaria • Vasculitis

Exploring Glucagon-Like Peptide-1 Receptor Agonists Usage Among Non-Diabetic Healthcare Providers: A Cross-Sectional Multi-Country Study. (PubMed, Health Sci Rep) - "Semaglutide (45.7%, 95% CI: 41.8%-49.5%) was the most commonly used GLP-1RA, followed by Liraglutide (36.9%, 95% CI: 33.2%-40.8%). Other GLP-1RAs were used less frequently, including Dulaglutide (17.0%, 95% CI: 14.2%-20.1%), Exenatide (14.1%, 95% CI: 11.5%-17.0%), Albiglutide (7.0%, 95% CI: 5.1%-9.2%), and Lixisenatide (8.5%, 95% CI: 6.5%-10.9%...This study provides the first prevalence estimate of GLP-1RA use among HCPs and GLP1-Ras users and explores the associations between demographic characteristics and perceptions of safety and efficacy. The findings highlight the self-prescribing practices of these medications for weight management and underscore the need for appropriate monitoring to avoid potential health risks."

Journal • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. (PubMed, Diabetes Obes Metab) - "The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose-lowering agents. However, larger therapeutic efficacy was not systematically associated with higher GI AE or drug discontinuation rates, indicating better tolerability of the more effective agents/preparations."

Clinical • Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

PERMEABILITY OF THE BLOOD-BRAIN BARRIER TO INCRETIN RECEPTOR AGONISTS (IRAS) (ADPD 2025) - "Results We found that the majority of IRAs cross the BBB to some degree with the most permeable being albiglutide, exenatide, and dulaglutide. Four IRAs (liraglutide, DA1-JC, semaglutide, and tirzepatide) have very low or no measurable uptake...There was a correlation between absolute charge and BBB penetration, suggesting uptake by the mechanism of adsorptive transcytosis. Conclusions These Results suggest that some IRAs may exert neuroprotective effects by acting behind the BBB."

Alzheimer's Disease • CNS Disorders • Diabetes • Metabolic Disorders • Movement Disorders • Parkinson's Disease

PREOPERATIVE GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST ASSOCIATED WITH IMPROVED POSTOPERATIVE OUTCOMES (IARS-SOCCA 2025) - "We first compared patients who were treated with a GLP1-RA (lixisenatide, albiglutide, tirzepatide, dulaglutide, liraglutide, semaglutide, or exenatide) within 6 months of a procedure with those who were not treated. This large analysis assessed the effects of holding GLP1-RAs before surgery on postoperative outcomes. GLP1-RAs may protect against postoperative aspiration and other adverse outcomes; holding GLP1-RA may be harmful."

Alzheimer's Disease • Anesthesia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Dementia • Diabetes • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Heart Failure • Hepatology • Infectious Disease • Liver Failure • Metabolic Disorders • Multiple Sclerosis • Myocardial Infarction • Nephrology • Obesity • Oncology • Pain • Pancreatitis • Pneumonia • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses? (PubMed, Nervenarzt) - "Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors and retatrutide is a triple GLP‑1, GIP and glucagon receptor agonist...Typical accompanying adverse reactions are gastrointestinal side effects, such as nausea, vomiting, diarrhea, eructation and gastroesophageal reflux. More severe side effects include pancreatitis, allergic reactions, renal function disorders and possibly an increased risk of thyroid cancer."

Journal • Review • Addiction (Opioid and Alcohol) • Allergy • Alzheimer's Disease • Binge Eating Disorder • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Depression • Diabetes • Endocrine Cancer • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Oncology • Pancreatitis • Psychiatry • Solid Tumor • Thyroid Gland Carcinoma

The Effects of GLP-1 Agonists on the Postoperative Complications of TKA Patients (AAOS 2025) - "Patients over the age of 18 with a history of GLP-1 agonist use (semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide, and albiglutide) before TKA, including use within at least one month of their surgery or anytime after (Group A), were compared to TKA patients with no history of GLP-1 agonist use (Group B). A history of GLP-1 agonist use was protective for several common postoperative complications of TKA patients at 30 days, 180 days, and 365 days after TKA compared to patients with no history of GLP-1 agonist use. Future research should be conducted regarding the dosage, chronicity, and recency of GLP-1 agonist use on TKA postoperative outcomes."

Clinical • Anemia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Depression • Diabetes • Dyslipidemia • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Nephrology • Obesity • Orthopedics • Osteoarthritis • Pain • Psychiatry • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatology

Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes. (PubMed, Eur Heart J Suppl) - "Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like exenatide, liraglutide, albiglutide, dulaglutide, and semaglutide, initially developed for treatment of Type 2 diabetes, have shown CV benefits, and international guidelines recommend now GLP-1 RAs as preferred drugs for CV prevention in diabetic patients regardless of baseline HbA1c or metformin use. Notably, independently by route of administration, semaglutide showed early CV benefits, suggesting mechanisms beyond glycaemic control or weight reduction. Semaglutide, combining potent cardio-metabolic effects with oral route, emerges as a pivotal treatment for high-risk Type 2 diabetes patients, offering comprehensive CV protection independent of HbA1c levels."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types. (PubMed, Geroscience) - "Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), albiglutide (Tanzeum), dulaglutide (Trulicity), lixisenatide (Lyxumia, Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound), are widely used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. In conclusion, GLP1R expression levels serve as an important biomarker with potential prognostic significance across multiple cancers, demonstrating both protective and adverse associations depending on the tumor type. These findings highlight the complex role of GLP-1R agonists in cancer risk and survival, suggesting that the therapeutic use of these agents should be carefully tailored to the individual patient's cancer risk profile."

Journal • Bladder Cancer • Breast Cancer • Cervical Cancer • Cervical Squamous Cell Carcinoma • Clear Cell Carcinoma • Clear Cell Renal Cell Carcinoma • Colon Cancer • Colorectal Cancer • Diabetes • Endocrine Cancer • Endometrial Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Genetic Disorders • Genito-urinary Cancer • Head and Neck Cancer • Hepatocellular Cancer • Hepatology • Lung Adenocarcinoma • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Obesity • Oncology • Ovarian Cancer • Pancreatic Cancer • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thyroid Gland Carcinoma • Type 2 Diabetes Mellitus • Uterine Cancer

The Role of Glucagon-Like Peptide-1 Agonists on Gastric Emptying Measured by Scintigraphy Imaging (ACG 2024) - "Search words included ("GLP1 agonists" OR "GLP-1 analog" OR "liraglutide" OR "semaglutide" OR "exenatide" OR "lixisenatide" OR "albiglutide" OR "dulaglutide" OR "Tirzepatide") AND ("Gastric emptying" OR "residual gastric food" OR "residual gastric content*"). We identified 10 studies on scintigraphy imaging in patients on GLP-1 agonists.(Table-1) There were 239 patients 144 patients on GLP-1 and 141 patients on placebo. The medications used were Exenatide (5), liraglutide (2), semaglutide (1), ROSE-010 (1), GLP-1 (7–36)amide (1). The commonest indication for usage was obesity, Type 2 DM."

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. (PubMed, Front Pharmacol) - "Our study aimed to characterize and evaluate AP associated with different GLP-1 RAs (exenatide, lixisenatide, liraglutide, albiglutide, semaglutide, dulaglutide and tirzepatide) in a public adverse events database and to review the relevant case reports. There is a notable reporting signal of AP associated with all GLP-1 RAs. Healthcare providers must remain vigilant and closely monitor this potentially life-threatening adverse event."

Adverse events • Journal • Real-world • Real-world evidence • Pancreatitis

Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis. (PubMed, Postgrad Med J) - "GLP-1RA is superior to SGLT2i in improving LVEF and reducing myocardial infarction/acute coronary syndrome, whereas DPP4i is superior to SGLT2i in improving LVEDV and LVESV. Key message What is already known on this topic-It has been confirmed that three new hypoglycemic drugs have a protective effect on the cardiovascular system. Studies have shown that sodium-dependent glucose transporter 2 inhibitors (SGLT2i) can improve cardiovascular outcomes and enhance the quality of life of heart failure patients. Currently, SGLT2i is widely used in the clinical treatment of heart failure, and related studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase inhibitor (DPP4i) also play important roles in the treatment of heart failure. What this study adds-However, there is no relevant research on whether these drugs' clinical efficacy is dose-dependent. How this study might affect research, practice, or policy-This study included..."

Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. (PubMed, Expert Opin Drug Saf) - "The RORs were significant for all agents within the class (ROR range: 2.64-61.12, all p < 0.008), including semaglutide, dulaglutide, exenatide, liraglutide, and tirzepatide compared to niacin. Inadequate access, availability, and affordability of GLP-1 RAs has contributed to the increased seeking via online and/or compounding pharmacies, and is associated with greater risk for prescription errors that differentially affect racial, ethnic and socioeconomic vulnerable populations. Pharmacovigilance database analyses cannot establish causation only association."

Journal

Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease - insights from the Harmony Outcomes trial. (PubMed, Eur J Prev Cardiol) - "In patients with type 2 diabetes, treatment with albiglutide, compared to placebo, reduced the risk of cardiovascular events irrespective of history of AF. Further, albiglutide treatment did not increase AF adverse events but was associated with a trend to a lower rate of AF events during follow-up without reaching statistical significance."

Journal • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system. (PubMed, Acta Diabetol) - "In a real-world pharmacovigilance setting, GLP-1RAs were associated with lower reporting of fracture-related AEs, indicating the protective effect of GLP-1RAs against fractures."

Adverse events • Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics

Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide. (PubMed, Endocr Pract) - "Traditional approaches, including lifestyle modification, and diverse drugs targeting a gastrointestinal hormone, including glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (Liraglutide, Semaglutide, Exenatide, Albiglutide, Dulaglutide, Lixisenatide, Orlistat, Phentermine/Topiramate, Lorcaserin, Sibutramine, Rimonabant) offer tailored strategies; yet their effectiveness is limited and some drugs were taken off the market. Its Food and Drug Administration (FDA) approval marks a milestone in the realm of obesity therapeutics. Going beyond a recapitulation of findings, the conclusion emphasizes the imperative for ongoing exploration and vigilant safety monitoring in tirzepatide's application."

Journal • Review • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. (PubMed, Front Pharmacol) - " A system organ class of metabolism and nutrition disorders was employed to filter AE reports, resulting in the identification of 10,450 reports for exenatide, 2,860 reports for liraglutide, 240 reports for albiglutide, 4,847 reports for dulaglutide, 2,905 reports for semaglutide, 1,089 reports for tirzepatide, and 13 reports for lixisenatide. Liraglutide, dulaglutide, semaglutide, and tirzepaptide's potential to induce dehydration, necessitates special attention. Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders."

Adverse events • Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "Albiglutide provides reassuring data on good glycemic efficacy, tolerability, and safety over an extended period of clinical use in patients with T2D. Albiglutide 30 mg has comparable efficacy and safety profiles to albiglutide 50 mg."

Clinical • Journal • Retrospective data • Review • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

GASTROPARESIS RISK IN PATIENTS WITH TYPE 2 DIABETES PRESCRIBED GLP-1 RECEPTOR AGONISTS (DDW 2024) - " We utilized the TriNetX multi-institutional database (~88 million patients) to examine the risk of new diagnosis of GP (ICD-10 code K31.84) in adult patients (age >18) with T2D who were prescribed GLP-1RAs (dulaglutide, semaglutide, liraglutide, lixisenatide, exenatide, tirzepatide, or albiglutide) between January 2021 and December 2022. We conclude an association between GLP-1RA prescription and increased GP risk in patients with T2D in this large study. We propose ongoing long-term clinical monitoring and further research in patients with T2D who are prescribed GLP analogs."

Clinical • Celiac Disease • CNS Disorders • Diabetes • Gastrointestinal Cancer • Gastrointestinal Disorder • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Oncology • Type 2 Diabetes Mellitus

BARIATRIC SURGERY VERSUS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS: A COMPARISON OF CARDIOVASCULAR OUTCOMES (DDW 2024) - "GLP-1 RAs evaluated in this study were dulaglutide exenatide liraglutide semaglutide albiglutide and lixisenatide. This large retrospective study found BS to be associated with a lower risk of adverse cardiovascular events compared with GLP-1 RA therapy. Further studies are needed to corroborate these findings."

Bariatric surgery • Surgery • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Genetic Disorders • Heart Failure • Myocardial Infarction • Obesity

ASSOCIATION BETWEEN PERIOPERATIVE GLP-1 AGONIST USE AND POST OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING UPPER ENDOSCOPY (DDW 2024) - "3%) were taking any GLP-1 agonist (semaglutide dulaglutide liraglutide lixisenatide exenatide albiglutide) or dual GLP-1/GIP receptor agonist (tirzeparide). This large data base study of more than 1000 patients does not show a statistically significant relationship between GLP-1 agonist use and retained gastric products aspiration events or postoperative vomiting."

Clinical • Anesthesia • Diabetes • Gastrointestinal Disorder • Metabolic Disorders

IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON BOWEL PREPARATION FOR COLONOSCOPY (DDW 2024) - "Cases were defined as patients on GLP-1 RAs (semaglutide dulaglutide albiglutide liraglutide) at the time of the procedure while controls were those not taking GLP-1 RAs. GLP-1 RAs are independently associated with lower quality bowel preparation suggesting that these medications may need to be held prior to colonoscopy procedures to improve colorectal cancer screening and surveillance."

Addiction (Opioid and Alcohol) • Colorectal Cancer • Diabetes • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Oncology • Solid Tumor

GLP-1 RECEPTOR AGONISTS RISING ROLE IN HEART FAILURE MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2024) - "A random-effects model was used to analyze pooled data. A total of nine RCTs comprising 8,170 patients were included, of whom 4,040 (49.4%) received were treated with GLP-1 RAs (semaglutide, dulaglutide, liraglutide, albiglutide, or exenatide). In this meta-analysis of RCTs of patients with HF, GLP-1 RAs were associated with an improvement in functional outcome 6-MWT, compared with placebo. Further studies are warranted to determine the clinical benefit of GLP-1 RA in HF management."

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

ALBIGLUTIDE AND ATRIAL FIBRILLATION / ATRIAL FLUTTER IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE - A SECONDARY ANALYSIS OF THE HARMONY OUTCOMES TRIAL (ACC 2024) - "Treatment with the GLP-1 receptor agonist albiglutide, compared to placebo, reduced the risk of major cardiovascular events as well as AF events in patients with and without AF at baseline."

Clinical • Atrial Fibrillation • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. (PubMed, Eur Neuropsychopharmacol) - "With the current pharmacovigilance approach, no causality link between suicidal ideation and use of any GLP-1 RA can be inferred. There is a need for further research and vigilance in GLP-1 RA prescribing, particularly in patients with co-existing psychiatric disorders."

Adverse events • Journal • CNS Disorders • Mental Retardation • Psychiatry • Suicidal Ideation